<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-one consecutive children with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) received prophylaxis therapy with the low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) enoxaparin during L-asparaginase treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Enoxaparin was given every 24 h subcutaneously at a median dose of 0.84 mg/kg per day (range, 0.45-1.33 mg/kg per day) starting at the first dose of L-asparaginase until 1 week after the last dose </plain></SENT>
<SENT sid="2" pm="."><plain>Molecular analysis for thrombophilic polymorphisms documented prothrombin G20210A mutation in 3/27 (11%), homozygosity for MTHFR C677T mutation in 5/27 (18.5%, and heterozygosity for <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> in 5/27 (18.5%) children </plain></SENT>
<SENT sid="3" pm="."><plain>There were no thrombotic events during 76 courses of L-asparaginase in 41 patients who had received enoxaparin </plain></SENT>
<SENT sid="4" pm="."><plain>One patient suffered brain <z:mpath ids='MPATH_124'>infarct</z:mpath> 7 days after enoxaparin was stopped </plain></SENT>
<SENT sid="5" pm="."><plain>There were no <z:mp ids='MP_0001914'>bleeding</z:mp> episodes </plain></SENT>
<SENT sid="6" pm="."><plain>In a historical control group of 50 ALL children who had not received prophylactic enoxaparin during L-asparaginase treatment, two had <z:hpo ids='HP_0001907'>thromboembolisms</z:hpo> (one <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and one <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>Enoxaparin is safe and seems to be effective in prevention of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in ALL patients during L-asparaginase therapy </plain></SENT>
<SENT sid="8" pm="."><plain>This study provides pilot data for a future randomized trial of the use of LMWH during ALL therapy for the prevention of asparaginase-associated thrombotic events </plain></SENT>
</text></document>